Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemfibrozil adjunct therapy for major depressive disorder
IRCT20090117001556N119Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Apr 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of gemfibrozil in major depressive disorder (MDD) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Severity of depression. Started Apr 2019; status: completed.
02
Drugs
gemfibrozil
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20090117001556N119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090117001556N119.